•  
  •  
  •  
  •  

2025-10-06 03:12:03

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth

Keywords Selected:  Biosimilar

Stock Report

  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
  • Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
  • EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
  • Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
  • CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
  • Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
  • CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
  • Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
  • Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept
  • Biocon Biologics announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
  • CuraTeQ obtains exclusive rights for BioFactura's Ustekinumab biosimilar
  • CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product
  • Biocon Biologics' Hulio® Biosimilar to Humira®, now available in the United States
  • Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
  • Lupin receives Health Canada approval for Rymti®, biosimilar Etanercept
  • Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to market Five Biosimilar Candidates in the Philippines
  • Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan

Latest Post

  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024